IL279595B2 - Aqueous liquid aptamer formulations binding to FGF2 and uses thereof - Google Patents
Aqueous liquid aptamer formulations binding to FGF2 and uses thereofInfo
- Publication number
- IL279595B2 IL279595B2 IL279595A IL27959520A IL279595B2 IL 279595 B2 IL279595 B2 IL 279595B2 IL 279595 A IL279595 A IL 279595A IL 27959520 A IL27959520 A IL 27959520A IL 279595 B2 IL279595 B2 IL 279595B2
- Authority
- IL
- Israel
- Prior art keywords
- aqueous liquid
- preparation binding
- aptamer preparation
- fgf2
- binding fgf2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018124390 | 2018-06-29 | ||
| PCT/JP2019/025766 WO2020004607A1 (ja) | 2018-06-29 | 2019-06-28 | アプタマー製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL279595A IL279595A (en) | 2021-03-01 |
| IL279595B1 IL279595B1 (en) | 2025-11-01 |
| IL279595B2 true IL279595B2 (en) | 2026-03-01 |
Family
ID=68986754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279595A IL279595B2 (en) | 2018-06-29 | 2019-06-28 | Aqueous liquid aptamer formulations binding to FGF2 and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210269802A1 (https=) |
| EP (1) | EP3815715B1 (https=) |
| JP (1) | JP7340264B2 (https=) |
| KR (1) | KR102841342B1 (https=) |
| CN (1) | CN112384246B (https=) |
| AU (1) | AU2019292134B2 (https=) |
| BR (1) | BR112020026634A2 (https=) |
| CA (1) | CA3105002A1 (https=) |
| ES (1) | ES2992308T3 (https=) |
| IL (1) | IL279595B2 (https=) |
| MX (1) | MX2020014124A (https=) |
| SG (1) | SG11202012933QA (https=) |
| TW (1) | TWI845521B (https=) |
| WO (1) | WO2020004607A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220137699A (ko) | 2020-02-06 | 2022-10-12 | 가부시키가이샤 리보믹 | 망막하 고반사 병소 또는 망막하 고반사 병소를 수반하는 망막 질환의 치료제 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5847086A (en) * | 1991-06-20 | 1998-12-08 | Centeon L.L.C. | Therapeutic fragments of von Willebrand factor |
| ZA200903562B (en) * | 2006-11-14 | 2010-07-28 | Ribomic Inc | Aptamer against midkine and use thereof |
| CN101317820B (zh) | 2007-04-19 | 2012-02-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 生物亲和性配体分子介导的靶向脂质体，其制 备及其应用 |
| WO2008150495A2 (en) * | 2007-06-01 | 2008-12-11 | Archemix Corp. | Vwf aptamer formulations and methods for use |
| JP2011515685A (ja) * | 2008-03-26 | 2011-05-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 基質結合ビーズを長期間保存する方法 |
| US9052323B2 (en) | 2009-08-27 | 2015-06-09 | The University Of Kansas | Osmolyte mixture for protein stabilization |
| EP2535410A4 (en) | 2010-02-12 | 2014-08-13 | Ribomic Inc | APTAMER FOR FGF2 AND USE THEREOF |
| WO2014116789A1 (en) * | 2013-01-25 | 2014-07-31 | Thymon, Llc | Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection |
| CA2943772C (en) * | 2014-03-24 | 2022-07-19 | Ribomic Inc. | Aptamer for fgf2 and use thereof |
| EP3161138A4 (en) * | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| JP2018124390A (ja) | 2017-01-31 | 2018-08-09 | 株式会社沖データ | 画像形成装置及び定着制御方法 |
-
2019
- 2019-06-28 ES ES19825285T patent/ES2992308T3/es active Active
- 2019-06-28 CN CN201980043745.7A patent/CN112384246B/zh active Active
- 2019-06-28 AU AU2019292134A patent/AU2019292134B2/en active Active
- 2019-06-28 MX MX2020014124A patent/MX2020014124A/es unknown
- 2019-06-28 BR BR112020026634-5A patent/BR112020026634A2/pt not_active Application Discontinuation
- 2019-06-28 WO PCT/JP2019/025766 patent/WO2020004607A1/ja not_active Ceased
- 2019-06-28 JP JP2020527674A patent/JP7340264B2/ja active Active
- 2019-06-28 CA CA3105002A patent/CA3105002A1/en active Pending
- 2019-06-28 TW TW108122887A patent/TWI845521B/zh active
- 2019-06-28 IL IL279595A patent/IL279595B2/en unknown
- 2019-06-28 US US17/256,368 patent/US20210269802A1/en active Pending
- 2019-06-28 KR KR1020217002648A patent/KR102841342B1/ko active Active
- 2019-06-28 SG SG11202012933QA patent/SG11202012933QA/en unknown
- 2019-06-28 EP EP19825285.0A patent/EP3815715B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019292134B2 (en) | 2025-07-10 |
| TW202012625A (zh) | 2020-04-01 |
| JP7340264B2 (ja) | 2023-09-07 |
| SG11202012933QA (en) | 2021-01-28 |
| EP3815715A4 (en) | 2022-03-16 |
| CA3105002A1 (en) | 2020-01-02 |
| JPWO2020004607A1 (ja) | 2021-07-15 |
| CN112384246A (zh) | 2021-02-19 |
| MX2020014124A (es) | 2021-05-31 |
| IL279595A (en) | 2021-03-01 |
| EP3815715B1 (en) | 2024-09-11 |
| BR112020026634A2 (pt) | 2021-04-06 |
| CN112384246B (zh) | 2025-02-21 |
| AU2019292134A1 (en) | 2021-02-11 |
| US20210269802A1 (en) | 2021-09-02 |
| EP3815715A1 (en) | 2021-05-05 |
| WO2020004607A1 (ja) | 2020-01-02 |
| IL279595B1 (en) | 2025-11-01 |
| KR102841342B1 (ko) | 2025-07-31 |
| TWI845521B (zh) | 2024-06-21 |
| EP3815715C0 (en) | 2024-09-11 |
| ES2992308T3 (es) | 2024-12-11 |
| KR20210025083A (ko) | 2021-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202003833B (en) | Conjugates and preparation and use thereof | |
| IL273631A (en) | Special hpv molecules bind | |
| SG11202001063QA (en) | Clec9a binding agents and use thereof | |
| ZA201906813B (en) | Antibody binding specifically to muc1 and use thereof | |
| IL267925B (en) | hsd17b13 variants and their uses | |
| IL265489B (en) | Recombinant binding proteins and their uses | |
| IL289415A (en) | Claudin-6 binding molecules and their use | |
| IL288314A (en) | Anti-tdp-43 binding molecules and uses thereof | |
| SG11201705583XA (en) | Cxcr4 binding molecules | |
| SG11201708848TA (en) | RGMa BINDING PROTEIN AND USE THEREOF | |
| GB201702091D0 (en) | Specific binding molecules | |
| EP3315513A4 (en) | Cd154 binding polypeptide and use thereof | |
| IL262036A (en) | Hyaluronic acid conjugates and uses thereof | |
| ZA201905513B (en) | Rorgamma modulators and uses thereof | |
| EP3352765A4 (en) | MIR-19 MODULATORS AND USES THEREOF | |
| PL3430913T3 (pl) | Kompozycja do wiązania mykotoksyn i jej zastosowanie | |
| IL269772A (en) | Barsica protein extract and its uses | |
| SG11201705602VA (en) | Pdgf-b /pdgf-bb binding variants of heparan sulphates | |
| IL279595A (en) | Aqueous liquid aptamer preparations bind to FGF2 and uses thereof | |
| IL247998A0 (en) | aptamer for fgf2 and used in it | |
| IL273671A (en) | Cornoline variants and their use | |
| EP3266870A4 (en) | Conjugate and use thereof | |
| IL268149A (en) | RORGAMMA modulators and their uses | |
| HUP1700012A2 (en) | Novel proteins and use thereof | |
| IL274964A (en) | Anti-chymase aptamer and its use |